Johnson & Johnson has announced plans to invest more than $2 billion in the development of a state-of-the-art biologics manufacturing facility in Wilson, North Carolina, to support the company's growing portfolio of biologic therapies for oncology, immunology, and neuroscience.

The move aligns with Johnson & Johnson's broader strategy to file or launch over 70 novel therapies and product expansions by the close of the decade.

“A strong, global supply chain is crucial, and we purposefully invest to ensure our transformational medicines reliably and efficiently reach patients around the world,” said Dapo Ajayi, vice president, Innovative Medicine Supply Chain, Johnson & Johnson. “We are investing in capacity and new technologies to enhance our industry-leading capabilities and ensure a resilient supply chain for the future."
The new facility will be equipped with cutting-edge technology to streamline and optimize biologics manufacturing processes. In addition to bolstering the company's global production capacity, the Wilson facility will employ approximately 420 full-time workers in highly skilled positions. Johnson & Johnson sees North Carolina as a pivotal region for biopharmaceutical manufacturing, benefiting from a well-established life sciences ecosystem and an abundance of local talent.

The project is set to begin construction in the first half of 2025, with plans to significantly scale the company's manufacturing operations to meet increasing demand. Once operational, the site is expected to play a key role in supporting Johnson & Johnson's long-term pipeline and product launch goals while contributing to the state's growing life sciences industry.

"North Carolina is an important hub for biopharmaceutical manufacturing and talent, and we are pleased to join this thriving life sciences ecosystem and become part of the Wilson community,” Ajayi added.

In August, in a bid to strengthen its position in the cardiovascular space, Johnson & Johnson announced plans to acquire V-Wave Ltd., a privately held company specializing in heart failure treatment technology, for $600 million upfront and an additional $1.1 billion based on regulatory approvals and commercial success.

Prior to that, Johnson & Johnson acquired Shockwave Medical in April for approximately $13.1 billion, a move poised to reshape the treatment landscape for cardiovascular disease.

Business Affairs Homepage